Deciphering the Roles of Innate Lymphoid Cells in Cancer.
Fiche publication
Date publication
janvier 2019
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr BRUCHARD Mélanie
Tous les auteurs :
Bruchard M, Ghiringhelli F
Lien Pubmed
Résumé
Cancer is a complex disease and the role played by innate lymphoid cells (ILCs) in cancer development has begun to be uncovered over recent years. We aim to provide an exhaustive summary of the knowledge acquired on the role of ILCs in cancer. ILCs are classified into 3 different categories, ILC1s, ILC2s, and ILC3s, each encompassing specific and unique functions. ILC1s exhibit NK cells characteristics and can exert anti-tumor functions, but surprisingly their IFNγ production is not associated with a better immune response. In response to TGF-β or IL-12, ILC1s were shown to exert pro-tumor functions and to favor tumor growth. ILC2s role in cancer immune response is dependent on cytokine context. The production of IL-13 by ILC2s is associated with a negative outcome in cancer. ILC2s can also produce IL-5, leading to eosinophil activation and an increased anti-tumor immune response in lung cancer. ILC3s produce IL-22, which could promote tumor growth. In contrast, ILC3s recognize tumor cells and facilitate leukocyte tumor entry, increasing anti-tumor immunity. In some contexts, ILC3s were found at the edge of tertiary lymphoid structures, associated with a good prognostic. We are at the dawn of our understanding of ILCs role in cancer. This review aims to thoroughly analyze existing data and to provide a comprehensive overview of our present knowledge on the impact of ILCs in cancer.
Mots clés
MDSC, cancer, cytokine, immunotherapy, innate lymphoid cells
Référence
Front Immunol. 2019 ;10:656